Your browser doesn't support javascript.
loading
Pharmacological inhibition of BCL-2 with the FDA-approved drug venetoclax impairs longitudinal bone growth.
Velentza, Lilly; Wickström, Malin; Kogner, Per; Ohlsson, Claes; Zaman, Farasat; Sävendahl, Lars.
Afiliação
  • Velentza L; Division of Pediatric Endocrinology, Department of Women's and Children's Health, Karolinska Institutet, Visionsgatan 4, BioClinicum J9:30, SE-171 64, Stockholm, Sweden. lilly.velentza@ki.se.
  • Wickström M; Childhood Cancer Research Unit, Department of Women's and Children's Health, Karolinska Institutet, Stockholm, Sweden.
  • Kogner P; Childhood Cancer Research Unit, Department of Women's and Children's Health, Karolinska Institutet, Stockholm, Sweden.
  • Ohlsson C; Astrid Lindgren Children's Hospital, Karolinska University Hospital, Stockholm, Sweden.
  • Zaman F; Centre for Bone and Arthritis Research, Department of Internal Medicine and Clinical Nutrition, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
  • Sävendahl L; Division of Pediatric Endocrinology, Department of Women's and Children's Health, Karolinska Institutet, Visionsgatan 4, BioClinicum J9:30, SE-171 64, Stockholm, Sweden.
Sci Rep ; 13(1): 8054, 2023 05 17.
Article em En | MEDLINE | ID: mdl-37198212
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Desenvolvimento Ósseo / Condrócitos Idioma: En Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Suécia
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Desenvolvimento Ósseo / Condrócitos Idioma: En Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Suécia